Judith Michelle Schlaeger

Dr. Judith Michelle Schlaeger

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2016 in Journal of Midwifery & Women's Health
Verified
Journal Article
Closed access
PDF file
JSJudith Michelle Schlaeger
Judith Michelle Schlaeger
EGElizabeth M. Gabzdyl
Elizabeth M. Gabzdyl
JBJeanie L. Bussell
Jeanie L. Bussell
NTNobuari Takakura
Nobuari Takakura
HYHiroyoshi Yajima
Hiroyoshi Yajima
DWDiana J. Wilkie
Diana J. Wilkie

19 December 2022 in Journal of Midwifery & Women's Health
Verified
Journal Article
Open access
JSJudith Michelle Schlaeger
Judith Michelle Schlaeger
JGJennifer E. Glayzer
Jennifer E. Glayzer
MVMichelle Villegas‐Downs
Michelle Villegas‐Downs
HLHongjin Li
Hongjin Li
EGEdward J. Glayzer
Edward J. Glayzer
BMBarbara L. McFarlin
Barbara L. McFarlin
Vulvodynia affects 7% of American women, yet clinicians often lack awareness of its presentation. It is underdiagnosed and often misdiagnosed as vaginitis. The etiology of vulvodynia remains unknown, making it difficult to identify or develop effective treatment methods. The purpose of this article is to (1) review the presentation and evaluation of vulvodynia, (2) review the research on vulvodynia treatments, and (3) aid the clinician in the selection of vulvodynia treatment methods. The level of evidence to support vulvodynia treatment varies from case series to randomized controlled trials (RCTs). Oral desipramine with 5% lidocaine cream, intravaginal diazepam tablets with intravaginal transcutaneous electric nerve stimulation (TENS), botulinum toxin type A 50 units, enoxaparin sodium subcutaneous injections, intravaginal TENS (as a single therapy), multimodal physical therapy, overnight 5% lidocaine ointment, and acupuncture had the highest level of evidence with at least one RCT or comparative effectiveness trial. Pre to posttest reduction in vulvar pain and/or dyspareunia in non‐RCT studies included studies of gabapentin cream, amitriptyline cream, amitriptyline with baclofen cream, up to 6 weeks’ oral itraconazole therapy, multimodal physical therapy, vaginal dilators, electromyography biofeedback, hypnotherapy, cognitive behavioral therapy, cold knife vestibulectomy, and laser therapy. There is a lack of rigorous RCTs with large sample sizes for the treatment of vulvodynia, rendering it difficult to determine efficacy of most treatment methods. Clinicians will be guided in the selection of best treatments for vulvodynia that have the highest level of evidence and are least invasive.

1 April 2015 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
JSJudith Michelle Schlaeger
Judith Michelle Schlaeger
NXNenggui Xu
Nenggui Xu
CMCheryl L. Mejta
Cheryl L. Mejta
CPChang G. Park
Chang G. Park
DWDiana J. Wilkie
Diana J. Wilkie

18 May 2018 in Journal of Midwifery & Women's Health
Verified
Journal Article
Closed access
PDF file
JSJudith Michelle Schlaeger
Judith Michelle Schlaeger
CSCynthia L. Stoffel
Cynthia L. Stoffel
JBJeanie L. Bussell
Jeanie L. Bussell
HCHui Yan Cai
Hui Yan Cai
MTMiho Takayama
Miho Takayama
NTNobuari Takakura
Nobuari Takakura

7 November 2021 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Open access
PDF file
JGJennifer E. Glayzer
Jennifer E. Glayzer
BMBarbara L. McFarlin
Barbara L. McFarlin
MCMarco Castori
Marco Castori
MSMarie L. Suarez
Marie L. Suarez
MMMonya C. Meinel
Monya C. Meinel
JSJudith Michelle Schlaeger
Judith Michelle Schlaeger
Vulvodynia is debilitating vulvar pain accompanied by dyspareunia (pain with sexual intercourse). Ehlers–Danlos syndromes (EDS) and hypermobility spectrum disorders (HSD) may represent a predisposing factor for vulvodynia given a high rate of dyspareunia in these conditions. We conducted an online survey of women with EDS or HSD to assess rates of dyspareunia and estimate rates of vulvodynia, report rates of comorbid conditions common to EDS or HSD and vulvodynia, and examine rates of conditions contributing to dyspareunia in women with EDS or HSD. Women with EDS or HSD (N = 1,146) recruited via social media were 38.2 ± 11.5 years old, primarily White (94.4%), and resided in the United States (78.5%). 63.7% of participants reported dyspareunia and 50% screened positive for vulvodynia. The rate of comorbid conditions common to EDS or HSD and vulvodynia were: irritable bowel syndrome, 6.5%; fibromyalgia, 40.0%; temporomandibular joint dysfunction, 56.4%; migraine, 6.7%; interstitial cystitis, 1.7%; and mast cell activation syndrome, 10.2%. Participants reporting dyspareunia also reported ovarian cysts, fibroids, or abdominal or pelvic scars, 47.5%; endometriosis, 26.5%; and genital lacerations, 19.3%. Women with EDS or HSD may have a higher rate of vulvodynia (50.0%) than women in the U.S. population at large (8%) and should be assessed for dyspareunia and vulvodynia.

1 December 2017 in Pain Management Nursing
Verified
Journal Article
Closed access
JSJudith Michelle Schlaeger
Judith Michelle Schlaeger
RMRobert E. Molokie
Robert E. Molokie
YYYingwei Yao
Yingwei Yao
MSMarie L. Suarez
Marie L. Suarez
JGJulie Golembiewski
Julie Golembiewski
GVGina Votta-Velis
Gina Votta-Velis